Skip to content

Electronic Pill Bottle Monitoring to Promote Medication Adherence for People With Multiple Sclerosis

Electronic Pill Bottle Monitoring to Promote Medication Adherence for People With Multiple Sclerosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04130256
Enrollment
85
Registered
2019-10-17
Start date
2019-11-15
Completion date
2021-01-26
Last updated
2021-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Medication adherence

Brief summary

People with multiple sclerosis (MS) have variable adherence to MS medications, making the full efficacy of disease modifying therapies unrealized and the assessment of true treatment failures challenging. Whereas some patients forget to take medications due to active lifestyles, others may have cognitive impairments that prevent them from organizing and planning their regular dosing schedules. An electronic pill cap (Pillsy) has been developed to record pill taking, timing, and set reminders through a mobile app. Data on adherence can be captured and analyzed remotely for health care provider review.

Detailed description

The investigators will enroll 85 adult patients, 18 years old and above, with relapsing remitting multiple sclerosis (RRMS), at the Massachusetts General Hospital MS Clinics in a pilot study of Pillsy electronic pill bottles. People with RRMS who are taking (1) fingolimod, (2) dimethyl fumarate, (3) terifluonomide, (4) diroximel fumarate, or (5) siponimod will be eligible. Patients must possess any type of smartphone capable of downloading the Pillsy application to be eligible. Per the Pillsy manufacturer, the Pillsy application is available on iPhones connected to the Apple App Store and smartphones running the Android operating system that are connected to the Google Play Store. Participants will be asked to use the Pillsy bottle for 90 days each. Participants will be randomized 1:1 to two conditions: 1) active reminders and 2) passive adherence tracking. Patients in the active reminders group will receive daily alerts through the Pillsy bottle, the Pillsy app, and their phone to remind them to take their pill. Patients in the passive adherence tracking group will not receive reminders and will instead have usual adherence monitored by the electronic pill bottle.

Interventions

Electronic bottles that can beep and blink to send medication use reminders, record medication use data, and upload medication use data to a secure server.

Sponsors

National Multiple Sclerosis Society
CollaboratorOTHER
Pillsy, Inc.
CollaboratorUNKNOWN
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Randomized 1:1 trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Ability to provide individual written consent * Ability to understand sufficient levels of English to use the Pillsy app * Ability to come to Massachusetts General Hospital for two study visits over a 90-day window OR ability to access Zoom for virtual study visits * Possess a smartphone * Willingness to follow the study protocol

Exclusion criteria

* Presence of an MS relapse requiring acute management and/or hospitalization * Daily medication provided by allied health care workers * Foreign travel preventing electronic remote monitoring * Expectation of discontinuation of the oral disease modifying therapy (DMT) in the upcoming 90 days for any reason

Design outcomes

Primary

MeasureTime frameDescription
Rate of perfect adherence90-days post-enrollmentPerfect adherence is defined as taking all scheduled pills +/-3 hours of scheduled dosing time

Secondary

MeasureTime frameDescription
Participant satisfaction90-days post-enrollmentParticipant satisfaction with the use of an electronic pill bottle and app

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026